your market intelligence analyst
Search Results
1,202 results
Your search is now limited to «Immunotherapy» expert search.
Technology Org 07/18/2019 08:50
Immunotherapies, particularly checkpoint inhibitors that reinvigorate exhausted T cells, have revolutionized the treatment of certain forms of cancer.
More from Technology Org:
Healio News 07/18/2019 08:00
Our plan is to study multiple types of cancer, starting with the cancers that already show a response to immunotherapies followed by those that rarely respond to it,” Minn said.
More from Healio News: 07/18/2019 07:49
Other criteria for either HR+ HER2- breast cancer or TNBC should be met as described for Cohort 1 and 2, respectively D. Cohort 4 i.
More from 07/18/2019 07:36
On the basis of cancer type, the cancer immunotherapy drug discovery outsourcing market is segmented into lung, breast, colorectal, melanoma, prostate, head and neck, ovarian and pancreatic.
More from
PR Newswire 07/18/2019 06:32
On July 23, 2014 , Ono and Bristol-Myers Squibb further expanded the companies' strategic collaboration agreement to jointly develop and commercialize multiple immunotherapies – as single agents and combination regimens – for patients with cancer in Japan , South Korea and Taiwan.
More from PR Newswire:
Bayer 07/18/2019 06:30
On July 23, 2014, Ono and Bristol-Myers Squibb further expanded the companies’ strategic collaboration agreement to jointly develop and commercialize multiple immunotherapies – as single agents and combination regimens – for patients with cancer in Japan, South Korea and Taiwan. 07/18/2019 05:06
Cancer therapies incorporating the immune system have been applied successfully for many years in the form of allogeneic stem-cell transplants to patients with leukemia in certain disease situations.
More from
PubMed News (NIH) 07/18/2019
Response to immunotherapy determined.
More from PubMed News (NIH):
The jump of melanoma cancer has been recorded in all ages, rising from the eighth most common cancer in Britain to the fifth most common cancer.
More from Mail on Sunday (United Kingdom):
Targeted Oncology 07/17/2019 16:00
Jane Lowe Meisel, MD Jane Lowe Meisel, MD, reviewed systemic therapy options for treating patients with breast cancer with a group of physicians during a Targeted Oncology live case-based peer perspectives discussion.
More from Targeted Oncology:
Onclive 07/17/2019 15:46
Matthew Powell, MD Single-agent immunotherapy has elicited minimal responses in patients with ovarian cancer, but the preclinical rationale for combinations with chemotherapy, antivascular therapy, and PARP inhibitors is strong and worthy of further pursuit, said Matthew Powell, MD.
More from Onclive:
The Scientist 07/17/2019 14:48
Messenger molecules such as cytokines are involved in the communication within the immune system and play a vital role in a variety of conditions including cancer and autoimmune diseases.
More from The Scientist:
FierceMedicalDevices 07/17/2019 09:14
The company says the changes come from its desire to “sharpen its focus” on human papillomavirus (HPV) cancers, which includes commercializing its (highly troubled) lead asset VGX-3100, a DNA-based immunotherapy to treat cervical dysplasia caused by HPV.
More from FierceMedicalDevices:
Physics World 07/17/2019 08:55
Alternative approaches Researchers from the Abramson Cancer Center at the University of Pennsylvania have assessed the effect of treating metastatic NSCLC patients with the immunotherapy drug pembrolizumab following locally ablative therapy.
More from Physics World:
Cleveland Clinic researcher Dr. Vincent Tuohy has been developing a method to vaccinate women against contracting breast cancer, focused specifically on triple negative breast cancer (TNBC), the most lethal form of the disease.
More from Healthcare Sales & Marketing Network:
PharmaTimes 07/17/2019 07:09
Boehringer Ingelheim has announced its acquisition of all shares of AMAL Therapeutics, a private Swiss biotechnology company focused on cancer immunotherapy.
More from PharmaTimes:
Genetic Literacy Project 07/17/2019 07:06
The evaluation and implementation of dasatinib as an on/off control drug in CAR-T cell immunotherapy should be feasible and straightforward,” the authors wrote.
More from Genetic Literacy Project:
pharmaphorum 07/17/2019 06:41
Seattle Genetics and Astellas have filed their antibody-drug conjugate enfortumab vedotin with the US drug regulator for advanced bladder cancer, after failure of chemotherapy and immunotherapy.
More from pharmaphorum:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications